Senomyx Inc. (SNMX)
Deutsche Bank 37th Annual Healthcare Conference Call
May 8 2012 4:10 pm ET
Kent Snyder – Chairman and Chief Executive Officer
Tony Rogers – Senior Vice President and Chief Financial Officer
Good afternoon everyone. I’m Barbara Ryan and welcome to Senomyx. It’s our pleasure to host them here this year. It’s a company that’s focused on using taste receptor technology to discover and develop flavor ingredients for the food, beverage and ingredient supply industries.
Joining me here on the podium, we have two presenters from the company, Kent Snyder, the Chief Executive Officer and Chairman of the Board of Directors; and the Chief Financial Officer, Tony Rogers, and I think they are both going to give us an overview of the company, and then we will open it up to your questions, thank you.
Thank you, Barbara. Thank you for attending today. Before we get started I should make the obligatory statement about our presentation that we maybe making certain forward-looking statements, during the presentation and then we would ask you to refer to our most recent SEC filings for a complete disclosure of risk factors.
So we are a little bit different type of company. This is a health care conference, so we’ll talk a little bit about some of the science behind Senomyx, but we are a company that utilize the tools and techniques that were learnt from the Bio-tech industry and have developed into a nearly what we taste science and which has led to the discovery of novel flavor ingredients for the food, beverage and flavor industry and the reason why we think this is important for carrying out the science is there is lot of health concerns about the foods and beverages that we consume.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts